Dariush Sheikholeslami-Vatani, Mohammad Reza Bolurian, Rahman Rahimi,
Volume 26, Issue 11 (2-2016)
Abstract
Background & aims: Some studies have shown that beta-alanine supplementation may delay fatigue during strenuous exercises. The aim of this study was the effect of 10 days β-alanine supplementation with different doses on neuromuscular fatigue and blood lactate levels. Material & methods: 40 active men with a mean age of 21.9±2.6 years and body mass index 24.54±1.8 kg/m2 were randomly divided into four groups of 10 people including: 2, 4 and 6 g doses of beta-alanine supplement (Experimental groups) and placebo (control) group. Competitors completed four 30-second Wingate tests with maximum power, before and after 10 days beta-alanine supplementation period. 4 minute rest interval was set between each exercise. The first blood sampling administrated before first exercise and second one after 6 minutes of fourth exercise. The EMG amplitude as neuromuscular fatigue index was measured before the first wingate and during the fourth wingate test. Results: the result showed that supplementation with different doses of β-alanine has no effect on M wave amplitude in vastus lateralis muscle. In other words, neither within-group (P=0.078) and between-group changes (P=0.66) was significant. Moreover, after repeated wingate exercises, amount of lactate in all groups (received β-alanine supplement and placebo group) increased significantly (p=0.000), while, no difference showed between groups (p=0.1). Conclusion: The present findings suggest that doing repetitive maximal exercises results in significant increase of lactate, but short-term β-alanine supplementation with different doses has no effect on neuromuscular fatigue and blood lactate accumulation.
Javad Pourdadash Shahrak, Bahman Alinezhad, Naser Masoudi,
Volume 35, Issue 5 (8-2024)
Abstract
Background & Aim: Acute limb ischemia remains a significant cause of emergency vascular surgery. Given the severe complications associated with this condition and the need for more effective treatments, this study was conducted to evaluate the impact of beta-alanine on clinical outcomes in patients with acute upper or lower limb ischemia following surgery.
Materials & Methods: This single-blind clinical trial enrolled 40 patients with acute limb ischemia without gangrene or mottling and who required amputation. Patients were randomly assigned to a beta-alanine group (n=20) or a placebo group (n=20). The intervention group received 4 grams of oral beta-alanine before surgery and 4 hours postoperatively, while the placebo group received a matching placebo. Primary outcomes included limb loss frequency and extent, while secondary outcomes were mortality and laboratory findings.
Results: A total of 9 patients (22.5%) experienced limb loss. Of these, only 1 patient (5%) was in the beta-alanine group, compared to 8 patients (40%) in the placebo group (p=0.02). In the beta-alanine group, the affected limb was the right lower extremity. In the placebo group, one patient lost the right upper limb, two lost the right lower limb, four lost the left upper limb, and one lost the left lower limb. There was no significant difference in mortality between the groups (5% in the beta-alanine group versus 15% in the placebo group; p=0.61).
Conclusion: The frequency of limb loss was significantly lower in patients treated with 4 grams of oral beta-alanine compared to the placebo group. Therefore, beta-alanine may be considered an effective adjunctive therapy in reducing the risk of limb loss in patients with acute limb ischemia.
